| Old Articles: <Older 6241-6250 Newer> |
|---|
 |
BusinessWeek
March 11, 2010
Margaret Cronin Fisk et al. |
Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.   |
BusinessWeek
March 11, 2010
Ellen Gibson |
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. |
BusinessWeek
March 11, 2010 |
Four Ways to Raise HDL Four different routes to raising good cholesterol. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
March 11, 2010
Brian Orelli |
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune. |
The Motley Fool
March 10, 2010
Brian Orelli |
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. |
The Motley Fool
March 10, 2010
Jennifer Schonberger |
A Key Representative Weighs In on Financial Reform and Health Care Paul Kanjorski, D-Pa, talks about what needs to change and what needs to get done on Capitol Hill. |
The Motley Fool
March 9, 2010
Brian Orelli |
Are Billions of Dollars in Revenue at Risk? Vaccine makers' lawsuit protection is called into question. |
The Motley Fool
March 9, 2010
Brian Orelli |
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. |
| <Older 6241-6250 Newer> Return to current articles. |
